



Please complete this Test Requisition Form in English

Sanofi Rare Disease  
Specialty Testing Program  
Royal Children's Hospital  
4th Floor, East Building  
50 Flemington Road  
Parkville, Victoria 3052 Australia  
61 3 9345 9806

☐ Fax

Send additional copy of report to: ( )

Account # 76001080

Account Bill Only

Patient's Legal Name (Last, First, MI)

Sex

☐ M

☐ F

Date of Birth

MO

DAY

YEAR

Collection Time

:

☐ AM

☐ PM

Collection Date

MO

DAY

YEAR

Clinician or Physician's / Authorized Name (Last, First)

Clinician or Physician's / Authorized Signature

Patient's ID #

Please check applicable treatment

☐ Aldurazyme®☐ Fabrazyme®☐ Nexviazyme®/  
☐ Cerezyme®☐ Myozyme®\*Nexviadyne®

Test Category: Adverse Event Hypersensitivity

Mark requested testing below:

- ☐ 504762 Laronidase (Aldurazyme) IgE Antibody
- ☐ 504758 Imiglucerase (Cerezyme) IgE Antibody
- ☐ 504754 Agalsidase beta (Fabrazyme) IgE Antibody
- ☐ 504766 Alglucosidase alfa (Myozyme) IgE Antibody
- ☐ 504880 Avalglucosidase alfa (Nexviazyme/Nexviadyne) IgE Antibody
- ☐ 504775 Complement Activation: C3a
- ☐ 504779 Mast Cell Activation Serum Tryptase

Sample Requirements:

Test Type	Collection Tube	Sample Type / Volume	Submission Tube	Sample Storage	Sample Stability	Shipping Temperature
Anti-drug IgE Antibody	Serum Separator Tube or Red Top	1 mL Serum	Transfer Tube	Preferred: ≤ -20°C (Frozen) Acceptable: 2°C to 8°C (Refrigerated)	Frozen: 24 months Refrigerated: 14 days	Frozen
Complement Activation	Lavendar (K2EDTA) top	1 mL Serum	Transfer Tube	≤ -20°C (Frozen)	1 month Do not allow sample to thaw	Frozen
Serum Tryptase	Serum Separator Tube or Red Top	1 mL Serum	Transfer Tube	Preferred: ≤ -20°C (Frozen) Acceptable: 2°C to 8°C (Refrigerated)	Frozen: 24 months Refrigerated: 14 days	Frozen

Testing for drug-specific IgE antibody, complement activation and tryptase may be warranted for patients who experience an infusion-associated reaction suspected to represent a Type 1 (IgE mediated) hypersensitivity reaction. Samples for complement activation and tryptase should be collected 1-3 hours after onset of reaction whereas samples for drug-specific IgE antibody should be collected at least 3 days after infusion or prior to subsequent infusion.

For questions, please contact the LabCorp Project Manager at [RareDiseaseProgram@labcorp.com](mailto:RareDiseaseProgram@labcorp.com).

\*Nexviadyne is only available in Europe.

Adverse events suspected to be associated with laronidase (Aldurazyme), imiglucerase (Cerezyme), agalsidase beta (Fabrazyme), alglucosidase alfa (Myozyme), and avalglucosidase alfa (Nexviazyme/Nexviadyne) should be reported directly to Sanofi Pharmacovigilance. Cerezyme, Fabrazyme, Myozyme, and Nexviazyme/Nexviadyne are registered trademarks of Genzyme Corporation. Sanofi is a registered trademark of Sanofi. Aldurazyme is a registered trademark of BioMarin/Genzyme LLC.